Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
LAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $3.04
Previous CloseN/A
Volume335.74K
Average Volume (3M)1.96M
Market Cap
$521.16M
Enterprise Value$440.21M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Feb 26, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding372,258,800
10 Day Avg. Volume1,851,791
30 Day Avg. Volume1,961,953
Standard Deviation0.24
R-Squared0.11
Alpha-0.00938
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.32
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.73
Enterprise Value/Ebitda-3.78
Forecast
1Y Price Target
$2.50Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Standard BioTools News
PremiumCompany Announcements
Standard BioTools Reports 2024 Revenue Achievements and Plans
PremiumCompany Announcements
Standard BioTools Announces CCO Jeremy Davis’s Departure---
Bulls Say, Bears Say
Bulls Say
Cost ManagementManagement continues to drive underlying progress in cost reduction and margin improvement, helping mitigate the tough spending environment.
Merger BenefitsThe merger with SLGC nearly doubles LAB's revenues, expands the TAM & strengthens the balance sheet.
Positive Long-term OutlookOur diligence has reflected a positive outlook for the SomaLogic technology, and ultimately long-term investors will be rewarded as the LAB thesis plays out over the next few years.
Bears Say
CFO DepartureThe CFO departure (personal reasons) is a negative surprise though mgmt is steadfast key drivers are unchanged.
Revenue Miss2Q revenue missed consensus ($37.2M < $48.2M), a notable miss after a solid 1Q where mgmt reiterated FY'24 guidance.
Systemic ChallengesTools are currently facing several systemic challenges, including tight pharma spending (~70% of SomaLogic customer base) and a constrained capex environment.
---
Ownership Overview
38.61% Insiders
8.50% Mutual Funds
0.15% Other Institutional Investors
42.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LAB FAQ
What was Standard BioTools’s price range in the past 12 months?
Standard BioTools lowest stock price was $1.17 and its highest was $3.04 in the past 12 months.
What is Standard BioTools’s market cap?
Standard BioTools’s market cap is $521.16M.
When is Standard BioTools’s upcoming earnings report date?
Standard BioTools’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were Standard BioTools’s earnings last quarter?
Standard BioTools released its earnings results on Oct 30, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.
Is Standard BioTools overvalued?
According to Wall Street analysts Standard BioTools’s price is currently Undervalued.
Does Standard BioTools pay dividends?
Standard BioTools does not currently pay dividends.
What is Standard BioTools’s EPS estimate?
Standard BioTools’s EPS estimate is -0.06.
How many shares outstanding does Standard BioTools have?
Standard BioTools has 372,258,800 shares outstanding.
What happened to Standard BioTools’s price movement after its last earnings report?
Standard BioTools reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 4.255%.
Which hedge fund is a major shareholder of Standard BioTools?
Currently, no hedge funds are holding shares in LAB
---
Standard BioTools Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (85.19% Upside)
$2.50 (85.19% Upside)
Blogger Sentiment
Bullish
LAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.00%
12-Months-Change
Fundamentals
Return on Equity
-69.68%
Trailing 12-Months
Asset Growth
100.88%
Trailing 12-Months
Company Description
Standard BioTools
Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
---
LAB Company Deck
---
LAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects mixed performance with notable operational efficiencies and cash position strengths, but offset by significant revenue declines and challenges in key segments and markets.Read More>---
LAB Stock 12 Month Forecast
Average Price Target
$2.50
▲(85.19% Upside)
Technical Analysis
Best Analysts Covering LAB
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-16.57%
assigned a buy rating 4 months ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -16.57% per trade.
---